245 related articles for article (PubMed ID: 36716560)
1. The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab.
Gou B; Yang P; Feng J; Li Y; Huang G; Shi J; Wen L; Guo X; Zheng P; Yu G
J Neuroimmunol; 2023 Mar; 376():578035. PubMed ID: 36716560
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.
Redenbaugh V; Flanagan EP
Neurotherapeutics; 2022 Apr; 19(3):808-822. PubMed ID: 35267170
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
4. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
5. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
6. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
[TBL] [Abstract][Full Text] [Related]
7. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ
Front Immunol; 2024; 15():1320094. PubMed ID: 38576611
[TBL] [Abstract][Full Text] [Related]
8. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
[TBL] [Abstract][Full Text] [Related]
9. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
[No Abstract] [Full Text] [Related]
10. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z
Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
12. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
Jarius S; Aktas O; Ayzenberg I; Bellmann-Strobl J; Berthele A; Giglhuber K; Häußler V; Havla J; Hellwig K; Hümmert MW; Kleiter I; Klotz L; Krumbholz M; Kümpfel T; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Tumani H; Wildemann B; Trebst C;
J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
[TBL] [Abstract][Full Text] [Related]
14. AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature.
Spiezia AL; Carotenuto A; Iovino A; Moccia M; Gastaldi M; Iodice R; Tedeschi E; Petracca M; Lavorgna L; d'Ambrosio A; Brescia Morra V; Lanzillo R
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498887
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
[TBL] [Abstract][Full Text] [Related]
16. Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD.
Kunchok A; Flanagan EP; Snyder M; Saadeh R; Chen JJ; Weinshenker BG; McKeon A; Pittock SJ
Mult Scler; 2021 Apr; 27(4):630-635. PubMed ID: 32633603
[TBL] [Abstract][Full Text] [Related]
17. Role of serostatus in pediatric neuromyelitis optica spectrum disorders: A nationwide multicentric study.
Solmaz I; Öncel IH; Konuşkan B; Erol I; Orgun LT; Yılmaz Ü; Ünalp A; Atasoy E; Aksoy E; Yılmaz D; Öztürk M; Karaca NB; Yılmaz S; Yiş U; Dündar NO; Parlak Ş; Vural A; Günbey C; Anlar B
Mult Scler Relat Disord; 2023 Sep; 77():104847. PubMed ID: 37393803
[TBL] [Abstract][Full Text] [Related]
18. Updates in NMOSD and MOGAD Diagnosis and Treatment: A Tale of Two Central Nervous System Autoimmune Inflammatory Disorders.
Cacciaguerra L; Flanagan EP
Neurol Clin; 2024 Feb; 42(1):77-114. PubMed ID: 37980124
[TBL] [Abstract][Full Text] [Related]
19. Double-negative neuromyelitis optica spectrum disorder.
Wu Y; Geraldes R; Juryńczyk M; Palace J
Mult Scler; 2023 Oct; 29(11-12):1353-1362. PubMed ID: 37740717
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
Ringelstein M; Ayzenberg I; Lindenblatt G; Fischer K; Gahlen A; Novi G; Hayward-Könnecke H; Schippling S; Rommer PS; Kornek B; Zrzavy T; Biotti D; Ciron J; Audoin B; Berthele A; Giglhuber K; Zephir H; Kümpfel T; Berger R; Röther J; Häußler V; Stellmann JP; Whittam D; Jacob A; Kraemer M; Gueguen A; Deschamps R; Bayas A; Hümmert MW; Trebst C; Haarmann A; Jarius S; Wildemann B; Grothe M; Siebert N; Ruprecht K; Paul F; Collongues N; Marignier R; Levy M; Karenfort M; Deppe M; Albrecht P; Hellwig K; Gold R; Hartung HP; Meuth SG; Kleiter I; Aktas O;
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34785575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
